Next-Generation Biomanufacturing Market

Next-Generation Biomanufacturing Market Outlook (2023 to 2033)

As per Future Market Insights, the next-generation biomanufacturing market is anticipated to attain a value pool of US$ 20 billion by 2023-end. Global adoption for next-generation biomanufacturing is expected to rise at a CAGR of 7.2% to US$ 40 billion in 2033.

Data Points	Key Statistics
Expected Market Value of Next-Generation Biomanufacturing in 2023	US$ 20 billion
Projected Market Value of Next-Generation Biomanufacturing in 2033	US$ 40 billion
Growth Rate (2023 to 2033)	7.2% CAGR

Drivers of the Next-Generation Biomanufacturing Market

• Growing Demand for Biopharmaceuticals: Biologics and biosimilars have seen significant growth in recent years, driving the demand for biomanufacturing processes. Biomanufacturing is an attractive option due to its cost-effectiveness, scalability, and production of high-quality products.

• Technological Advancements: Advancements in biomanufacturing technologies have resulted in increased efficiency, cost-effectiveness, and production of high-quality biologics. Emerging technologies such as single-use systems, continuous manufacturing, and process automation are driving market growth.

Opportunities for Next-Generation Biomanufacturing Market

• Emergence of Continuous Biomanufacturing: Continuous biomanufacturing offers several advantages over traditional batch processes, such as increased efficiency, reduced costs, and improved product quality. The emergence of continuous biomanufacturing is expected to drive the growth of the biomanufacturing market.
• Increasing Use of Analytics and Data Science: The use of analytics and data science in biomanufacturing can help to improve efficiency, reduce costs, and increase product quality. Data analytics can be used to optimize biomanufacturing processes, monitor product quality, and predict potential issues before they occur.

Trends in Next-Generation Biomanufacturing Market

• Emphasis on Quality by Design (QbD): Quality by Design (QbD) is a systematic approach to the development and manufacturing of biologics, which emphasizes quality and risk management throughout the product lifecycle. The adoption of QbD is a growing trend in the biomanufacturing market, as it helps to ensure consistent quality and reduce the risk of product recalls.
• Focus on Sustainability: There is a growing focus on sustainability in the biomanufacturing industry, as companies are looking to reduce their environmental footprint. This trend is driving the development of eco-friendly biomanufacturing processes, such as the use of renewable energy sources and the reduction of waste and emissions.
• Application of Artificial Intelligence (AI): The application of AI in biomanufacturing is a growing trend, as it has the potential to improve efficiency, reduce costs, and increase product quality. Here are several noteworthy factors to take into account:
• Optimization of Biomanufacturing Processes: AI can be used to optimize biomanufacturing processes, reducing the need for trial-and-error and saving time and money. For example, AI algorithms can analyze large data sets to identify the optimal conditions for cell growth and product expression.
• Predictive Maintenance and Quality Control: AI can be used to predict equipment failure and other issues, enabling proactive maintenance and reducing downtime. AI can also be used to monitor product quality in real-time, identifying potential issues before they occur and improving product consistency.
• Personalized Medicine: AI can be used to analyze patient data and develop personalized medicine solutions. For example, AI algorithms can analyze genomic data to identify patients who are likely to respond to a particular treatment, enabling more targeted and effective therapies.
• Drug Discovery and Development: AI can be used to accelerate the drug discovery and development process, reducing costs and time-to-market. For example, AI algorithms can analyze large data sets to identify potential drug candidates and predict their efficacy and safety.

Overall, the application of AI in biomanufacturing is a rapidly evolving field with enormous potential to transform the industry. As AI technologies continue to advance, we can expect to see even greater efficiency, cost savings, and improved product quality in the biomanufacturing market.

The sudden progression of the biopharmaceutical industries represents the rising importance of the biomanufacturing as the chief procedure for the evolution and manufacture of the biological-based products, this is called the next-generation biomanufacturing market.

Next-generation biomanufacturing products are developed to provide consistent services that is better as compared to the first generation biomanufacturing products both in terms of quality and efficiency. Next-generation biomanufacturing market is focusing towards the use of single-use products such as single-use bio-containers and single-use bio-reactors, this is the most popular trends in the next generation biomanufacturing market.

This has led to the large numbers of advantages in the next-generation biomanufacturing market such as the reduced risk of contamination of products, adoption of cost savings facilities. The outbreak of novel coronavirus is believed to have an enduring impact on biopharmaceutical manufacturing.

Due to the COVID-19 pandemic, development of vaccines has become the main goal of the biomanufacturing industries. The development of advanced vaccines will also influence the growth of the biopharmaceutical industry post coronavirus pandemic.

Scientists and engineers are now focusing to develop the next-generation biomanufacturing functioning that can produce advanced vaccines in a cost-effective manner. They are also focusing on the quantities of the vaccines which would be needed to respond to future outbreaks and pandemic.

Rising number of biopharmaceutical companies across the world is expected to drive the next generation bio-manufacturing market in the forecast period. The need for advanced biomanufacturing to fulfil the demand of the patients is expected to boost up the growth of the next-generation biomanufacturing market.

Increasing investment of government and private organizations on the development of the innovative technology is expected to further boost various opportunities which in turn will lead to the growth of next-generation biomanufacturing market.

Many companies innovating products to enter into the next-generation biomanufacturing market, various novel next-generation biomanufacturing products are expected to be launched which would drive the growth of the next-generation biomanufacturing market.

Increasing awareness among the people regarding the benefits of the next-generation bio-manufacturing market would lead to the growth of the market. Based on the type, upstream biomanufacturing is expected to be the preferred process in the global next-generation biomanufacturing market.

Based on the application, the monoclonal antibody product segment is expected to dominate the next-generation due to high rate of products approval. Monoclonal antibodies to be followed by vaccines due to the current outbreak of novel coronavirus.

Based on end-user, biopharmaceutical companies are expected to be the major contributor of the revenue in the next-generation biomanufacturing market. North America is expected to dominate the next-generation biomanufacturing market due to the higher adoption of advanced technology and the prevalence of manufacturing industries in the region.

North America is expected to be followed by Europe. Asia-Pacific is expected to be the fastest-growing next-generation biomanufacturing market due to the rising population in countries like India and China. Latin America market is expected to experience the constant growth rate in the next-generation bio-manufacturing market whereas the Middle East & Africa expected to be the least profitable market due to lower adoption of advanced technology.

The major players operating in the global next-generation biomanufacturing market are

• Sartorius AG
• Merck &Co.
• Meissner Filtration
• ESCO Group LLC
• Solaris Biotechnology Applikon Biotechnology
• GEA Group AG
• PBS Biotech Inc.,
• bbi-biotech GmbH
• Danaher
• Corporation
• bbi-biotech GmbH

The report covers exhaustive analysis on

• Next-generation biomanufacturing Market Segments
• Next-generation biomanufacturing Market Dynamics
• Historical Actual Market Size, 2015 to 2019
• Next-generation biomanufacturing Market Size & Forecast 2020 to 2030
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Next-Generation Bio-Manufacturing Market Segment

The global next-generation bio-manufacturing market has been segmented based on workflow type, application and end-user.

By Workflow Type:

• Upstream Biomanufacturing Workflow
• Single-Use Upstream Biomanufaturing Workflow
• Downstream Biomanufaturing Workflow

By Application:

• Monoclonal Antibodies
• Vaccines
• Recombinant protein
• Hormones
• Others

By End-user:

• Biopharmaceutical Companies
• Research Institutions
• Contract Research Organizations